home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  November 13, 2018
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 548 active entries

Immunitor Inc.

365-2906 West Broadway
Vancouver V6K 2G8
Canada

Phone: 1 301 4760930
Fax: 1-775-640-6636 (USA)
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Immunitor Inc (Company) is incorporated in 2010 in Vancouver, Canada as licensee of Immunitor USA Inc., incorporated in 2004 in Maryland, USA. The Company has in-house developed patented products and currently manufactures several immunotherapies as means of preventing and/or treating viral (V1), bacterial (V2), fungal (V4) infections; chronic hepatits B and C (V5), atherosclerosis (V6), tuberculosis (V7), renal failure (V8), thyroid dysfunction (V-Hep), libido (HAP-V), cholangiocarcinoma (V3-X), pancreatic cancer (V3-P), and broad spectrum solid tumors (V3), endometriosis (V-Endo) and neurodegenerative disorders (V-Boost). The latest immunotherapy, hepcortespenlisimut-L, received orphan drug designation form the US FDA in 2014 and is currently in phase III clinical trial for liver cancer designation (Hepko-V5). The licensed technology is unique since it enables to formulate any protein or vaccine (recombinant or from natural source) as an oral pill, which is easy to administer, has low manufacturing cost, stable, safe, and effective. No other technology exists that could compete with Immunitor’s breakthrough invention which will reshape the vaccine and therapeutic protein industry. Company has recently added subsidiary companies in Hong Kong, Beijing, Ulaanbaatar and Moscow.   

Selected Categories:

Product Company   Service Company
Biopharma
- General
Biotech
- General
Supplier
- Distributor
Consulting
- General
Contract
- Production

Last update of this entry: November 09, 2017

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.